Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

Conclusions
These 8-year results provide further evidence supporting early initiation of treatment with IFNB1b in patients with a first event suggestive of MS.

Source: Journal of Neurology, Neurosurgery and Psychiatry - October 17, 2014 Category: Neurosurgery Authors: Edan, G., Kappos, L., Montalban, X., Polman, C. H., Freedman, M. S., Hartung, H.-P., Miller, D., Barkhof, F., Herrmann, J., Lanius, V., Stemper, B., Pohl, C., Sandbrink, R., Pleimes, D., for the BENEFIT Study Group Tags: JNNP Patients' choice, Open access, Immunology (including allergy), Multiple sclerosis Source Type: research